Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
-
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2023 totaled
$253.5 million -
Net product revenues for the first quarter 2023 totaled
$231.5 million 23% increase over the same quarter of prior year
“We are pleased to report another strong quarter of performance serving the Duchenne community. With EXONDYS 51, VYONDYS 53, and AMONDYS 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching
First Quarter 2023 and Recent Developments:
-
FDA advisory committee meeting for SRP-9001 to be held on May 12, 2023: In March, the Company announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the
U.S. Food and Drug Administration’s Office of Therapeutic Products determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. In April, Sarepta announced May 12, 2023 as the date of theU.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 BLA. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy. - SRP-5051-201 MOMENTUM Part B clinical trial fully enrolled: Sarepta has completed enrollment for Part B of the MOMENTUM clinical trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Data from Part B is expected in the second half of this year. If successful, Sarepta anticipates Part B to serve as the pivotal study for SRP-5051 and plans to seek accelerated approval for the candidate.
-
On track to complete enrollment in 2H23 for VOYAGENE clinical trial: VOYAGENE, or Study SRP-9003-201, is Sarepta’s phase 1 study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E). It is a
U.S. -only study enrolling ambulant patients aged 18 years or older and non-ambulant patients aged 4 to 50 years old, using clinical process SRP-9003 material. The Company has already seen positive expression and functional data in their first clinical trial, SRP-9003-101, and is conducting VOYAGENE to gain insights into a broader patient population. Sarepta expects to complete enrollment for VOYAGENE in the second half of 2023 and to begin their phase 3 study using commercially representative process material by the end of this year.
Conference Call
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
Financial Results
On a GAAP basis, for the three months ended March 31, 2023, the Company reported a net loss of
Revenues
For the three months ended March 31, 2023, the Company recorded total revenues of
For the three months ended March 31, 2023, the Company recorded net product revenues of
For both the three months ended March 31, 2023 and 2022, the Company recognized
Cost and Expenses
Cost of sales (excluding amortization of in-licensed rights)
For the three months ended March 31, 2023, cost of sales (excluding amortization of in-licensed rights) was
Research and development
Research and development expenses were
-
$15.6 million -
$14.0 million -
$10.5 million -
$6.5 million -
$3.3 million -
$2.8 million -
$2.7 million -
$1.5 million -
$2.5 million
Non-GAAP research and development expenses were
Selling, general and administrative
Selling, general and administrative expenses were
-
$17.8 million -
$11.0 million -
$8.7 million -
$1.7 million
Non-GAAP selling, general and administrative expenses were
Amortization of in-licensed rights
For both the three months ended March 31, 2023 and 2022, the Company recorded amortization of in-licensed rights of approximately
Loss on debt extinguishment
On November 14, 2017, the Company issued
Other income (expense), net
For the three months ended March 31, 2023 and 2022, other income, net was
Income tax expense
Income tax expense for the three months ended March 31, 2023 and 2022 was approximately
Cash, Cash Equivalents, Restricted Cash and Investments
The Company had approximately
Use of Non-GAAP Measures
In addition to the GAAP financial measures set forth in this press release, the Company has included certain non-GAAP measurements. The non-GAAP loss is defined by the Company as GAAP net loss excluding interest (income) expense, net, income tax expense, depreciation and amortization expense, stock-based compensation expense and other items. Non-GAAP research and development expenses are defined by the Company as GAAP research and development expenses excluding depreciation and amortization expense, stock-based compensation expense and other items. Non-GAAP selling, general and administrative expenses are defined by the Company as GAAP selling, general and administrative expenses excluding depreciation and amortization expense, stock-based compensation expense and other items.
1. Interest, tax, depreciation and amortization
Interest (income) expense, net amounts can vary substantially from period to period due to changes in cash and debt balances and interest rates driven by market conditions outside of the Company’s operations. Tax amounts can vary substantially from period to period due to tax adjustments that are not directly related to underlying operating performance. Depreciation expense can vary substantially from period to period as the purchases of property and equipment may vary significantly from period to period and without any direct correlation to the Company’s operating performance. Amortization expense primarily associated with in-licensed rights as well as patent costs are amortized over a period of several years after acquisition or patent application or renewal and generally cannot be changed or influenced by management.
2. Stock-based compensation expenses
Stock-based compensation expenses represent non-cash charges related to equity awards granted by the Company. Although these are recurring charges to operations, the Company believes the measurement of these amounts can vary substantially from period to period and depend significantly on factors that are not a direct consequence of operating performance that is within the Company’s control. Therefore, the Company believes that excluding these charges facilitates comparisons of the Company’s operational performance in different periods.
3. Other items
The Company evaluates other items of expense and income on an individual basis. It takes into consideration quantitative and qualitative characteristics of each item, including (a) nature, (b) whether the items relate to the Company’s ongoing business operations, and (c) whether the Company expects the items to continue on a regular basis. These other items include loss on debt extinguishment and impairment of equity investments.
- The Company excludes from its non-GAAP results the loss on debt extinguishment, which is considered to be a non-recurring event as it is associated with a distinct financing decision and is not indicative of the performance of the Company’s core operations, which accordingly would make it difficult to compare the Company’s results to peer companies that also provide non-GAAP disclosures.
- The Company excludes from its non-GAAP results the impairment of any equity investments as it is a non-cash item and is not considered to be a normal operating expense due to the variability of amount and lack of predictability as to the occurrence and/or timing of such impairments.
The Company uses these non-GAAP measures as key performance measures for the purpose of evaluating operational performance and cash requirements internally. The Company also believes these non-GAAP measures increase comparability of period-to-period results and are useful to investors as they provide a similar basis for evaluating the Company’s performance as is applied by management. These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP. Use of the terms non-GAAP research and development expenses, non-GAAP selling, general and administrative expenses, non-GAAP other income and loss adjustments, non-GAAP income tax expense, non-GAAP net loss, and non-GAAP basic and diluted net loss per share may differ from similar measures reported by other companies, which may limit comparability, and are not based on any comprehensive set of accounting rules or principles. All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”
About EXONDYS 51
EXONDYS 51 (eteplirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion, or “skipping”, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
EXONDYS 51 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information About EXONDYS 51
Hypersensitivity reactions, bronchospasm, chest pain, cough, tachycardia, and urticaria have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.
Adverse reactions in Duchenne patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least
The most common adverse reactions from observational clinical studies (N=163) seen in greater than
For further information, please see the full Prescribing Information.
About VYONDYS 53
VYONDYS 53 (golodirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
VYONDYS 53 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information for VYONDYS 53
Hypersensitivity reactions, including rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the VYONDYS 53 therapy.
Kidney toxicity was observed in animals who received golodirsen. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in Duchenne patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Adverse reactions observed in at least
Other adverse reactions that occurred at a frequency greater than
For further information, please see the full Prescribing Information.
About AMONDYS 45
AMONDYS 45 (casimersen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
AMONDYS 45 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information for AMONDYS 45
AMONDYS 45 is contraindicated in patients with known hypersensitivity to casimersen or to any of the inactive ingredients. Instances of hypersensitivity, including angioedema and anaphylaxis, have occurred in patients receiving AMONDYS 45. If a hypersensitivity reaction occurs, institute appropriate medical treatment, and consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 infusion and monitor until the condition resolves.
Kidney toxicity was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with AMONDYS 45, kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in Duchenne patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Adverse reactions observed in at least
Other adverse reactions that occurred in at least
For further information, please see the full Prescribing Information.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Forward-Looking Statements
In order to provide Sarepta’s investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs and technologies; the potential benefits of our technologies and scientific approaches; the potential benefits of our product candidates; our upcoming Advisory Committee meeting for SRP-9001 on May 12, including sharing the totality of evidence supporting the safety and efficacy of SRP-9001 at such meeting; the May 29, 2023 regulatory action date for our BLA for SRP-9001; a potential launch of SRP-9001 in
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; certain programs may never advance in the clinic or may be discontinued for a number of reasons, including regulators imposing a clinical hold and us suspending or terminating clinical research or trials; products intended for use in gene therapies are novel, complex and difficult to manufacture and we could experience production problems that result in delays in our development or commercialization of gene therapy programs, limit the supply of our product candidates or future approved products or otherwise harm our business; only a few gene therapy products have been approved in the
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Sarepta Therapeutics, Inc. |
||||||||
Condensed Consolidated Statements of Operations |
||||||||
(unaudited, in thousands, except per share amounts) |
||||||||
|
|
For the Three Months Ended
|
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Revenues: |
|
|
|
|
|
|
||
Products, net |
|
$ |
231,495 |
|
|
$ |
188,825 |
|
Collaboration |
|
|
22,005 |
|
|
|
22,005 |
|
Total revenues |
|
|
253,500 |
|
|
|
210,830 |
|
Cost and expenses: |
|
|
|
|
|
|
||
Cost of sales (excluding amortization of in-licensed rights) |
|
|
35,017 |
|
|
|
31,443 |
|
Research and development |
|
|
245,679 |
|
|
|
194,250 |
|
Selling, general and administrative |
|
|
110,714 |
|
|
|
71,840 |
|
Amortization of in-licensed rights |
|
|
178 |
|
|
|
178 |
|
Total cost and expenses |
|
|
391,588 |
|
|
|
297,711 |
|
Operating loss |
|
|
(138,088 |
) |
|
|
(86,881 |
) |
Other loss, net: |
|
|
|
|
|
|
||
Loss on debt extinguishment |
|
|
(387,329 |
) |
|
|
— |
|
Other income (expense), net |
|
|
12,707 |
|
|
|
(17,265 |
) |
Total other loss, net |
|
|
(374,622 |
) |
|
|
(17,265 |
) |
|
|
|
|
|
|
|
||
Loss before income tax expense |
|
|
(512,710 |
) |
|
|
(104,146 |
) |
Income tax expense |
|
|
4,045 |
|
|
|
879 |
|
Net loss |
|
$ |
(516,755 |
) |
|
$ |
(105,025 |
) |
|
|
|
|
|
|
|
||
Net loss per share — basic and diluted |
|
$ |
(5.86 |
) |
|
$ |
(1.20 |
) |
|
|
|
|
|
|
|
||
Weighted average number of shares of common stock used in computing basic and diluted net loss per share |
|
|
88,186 |
|
|
|
87,253 |
|
Sarepta Therapeutics, Inc. |
|
|||||||
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures |
|
|||||||
(unaudited, in thousands, except per share amounts) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
For the Three Months Ended
|
|
|||||
|
|
2023 |
|
|
2022 |
|
||
|
|
|
|
|
|
|
||
GAAP net loss |
|
$ |
(516,755 |
) |
|
$ |
(105,025 |
) |
Interest (income) expense, net |
|
|
(12,992 |
) |
|
|
15,581 |
|
Income tax expense |
|
|
4,045 |
|
|
|
879 |
|
Impairment of equity investment |
|
|
321 |
|
|
|
— |
|
Loss on debt extinguishment |
|
|
387,329 |
|
|
|
— |
|
Depreciation and amortization expense |
|
|
11,305 |
|
|
|
10,719 |
|
Stock-based compensation expense |
|
|
41,250 |
|
|
|
29,198 |
|
Non-GAAP net loss |
|
$ |
(85,497 |
) |
|
$ |
(48,648 |
) |
|
|
|
|
|
|
|
||
Non-GAAP net loss per share: |
|
|
|
|
|
|
||
Basic and diluted |
|
$ |
(0.97 |
) |
|
$ |
(0.56 |
) |
|
|
|
|
|
|
|
||
Weighted average number of shares of common stock used in computing earnings per share: |
|
|
|
|
|
|
||
Basic and diluted |
|
|
88,186 |
|
|
|
87,253 |
|
|
|
|
|
|
|
|
||
|
|
For the Three Months Ended
|
|
|||||
|
|
2023 |
|
|
2022 |
|
||
GAAP research and development expenses |
|
$ |
245,679 |
|
|
$ |
194,250 |
|
Stock-based compensation expense |
|
|
(16,413 |
) |
|
|
(13,068 |
) |
Depreciation and amortization expense |
|
|
(8,551 |
) |
|
|
(8,022 |
) |
Non-GAAP research and development expenses |
|
$ |
220,715 |
|
|
$ |
173,160 |
|
|
|
|
|
|
|
|
||
|
|
For the Three Months Ended
|
|
|||||
|
|
2023 |
|
|
2022 |
|
||
GAAP selling, general and administrative expenses |
|
$ |
110,714 |
|
|
$ |
71,840 |
|
Stock-based compensation expense |
|
|
(24,837 |
) |
|
|
(16,130 |
) |
Depreciation and amortization expense |
|
|
(2,576 |
) |
|
|
(2,519 |
) |
Non-GAAP selling, general and administrative expenses |
|
$ |
83,301 |
|
|
$ |
53,191 |
|
Sarepta Therapeutics, Inc. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(unaudited, in thousands, except share and per share data) |
||||||||
|
|
As of
|
|
|
As of
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
871,668 |
|
|
$ |
966,777 |
|
Short-term investments |
|
|
1,010,429 |
|
|
|
1,022,597 |
|
Accounts receivable |
|
|
223,836 |
|
|
|
214,628 |
|
Inventory |
|
|
202,675 |
|
|
|
203,968 |
|
Other current assets |
|
|
179,769 |
|
|
|
149,891 |
|
Total current assets |
|
|
2,488,377 |
|
|
|
2,557,861 |
|
Property and equipment, net |
|
|
182,862 |
|
|
|
180,037 |
|
Right of use assets |
|
|
62,016 |
|
|
|
64,954 |
|
Non-current inventory |
|
|
164,144 |
|
|
|
162,545 |
|
Other non-current assets |
|
|
162,387 |
|
|
|
162,969 |
|
Total assets |
|
$ |
3,059,786 |
|
|
$ |
3,128,366 |
|
|
|
|
|
|
|
|
||
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
106,710 |
|
|
$ |
95,875 |
|
Accrued expenses |
|
|
345,554 |
|
|
|
418,996 |
|
Deferred revenue, current portion |
|
|
67,239 |
|
|
|
89,244 |
|
Other current liabilities |
|
|
17,381 |
|
|
|
15,489 |
|
Total current liabilities |
|
|
536,884 |
|
|
|
619,604 |
|
Long-term debt |
|
|
1,234,284 |
|
|
|
1,544,292 |
|
Lease liabilities, net of current portion |
|
|
53,931 |
|
|
|
57,578 |
|
Deferred revenue, net of current portion |
|
|
485,000 |
|
|
|
485,000 |
|
Contingent consideration |
|
|
36,900 |
|
|
|
36,900 |
|
Other non-current liabilities |
|
|
38 |
|
|
|
42 |
|
Total liabilities |
|
|
2,347,037 |
|
|
|
2,743,416 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
9 |
|
|
|
9 |
|
Additional paid-in capital |
|
|
5,140,150 |
|
|
|
4,296,841 |
|
Accumulated other comprehensive loss, net of tax |
|
|
(419 |
) |
|
|
(1,664 |
) |
Accumulated deficit |
|
|
(4,426,991 |
) |
|
|
(3,910,236 |
) |
Total stockholders’ equity |
|
|
712,749 |
|
|
|
384,950 |
|
Total liabilities and stockholders’ equity |
|
$ |
3,059,786 |
|
|
$ |
3,128,366 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502006063/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
